The Indian stock market outlook for next week will be guided by several domestic and international cues such as retail inflation, quarterly results, US jobless claims data and others.
Pharmaceutical major Cipla on Tuesday reported a 49 per cent year-on-year (YoY) increase in its consolidated net profit for the December quarter (Q3 FY25) at Rs 1,574.6 crore, from Rs 1,068.5 crore in the same quarter last year (Q2 FY25).
Cipla's earnings before interest, tax, depreciation, and amortisation (EBITDA) jumped nearly 16% year-on-year to Rs 1,989 crore, according to the statement.
Indian regulator Central Drugs Standard Control Organisation (CDSCO) has approved Cipla to exclusively distribute and market inhaled insulin in the country, the drugmaker said on Wednesday.
Drug makers Cipla and Glenmark are recalling their products from the US market due to manufacturing issues.
NTPC, Coal India, Cipla, L&T and Tata Steel were top performers, while Britannia, Eicher, HUL, HDFC Bank and Nestle were…
Pharmaceutical firm Cipla has announced a 10.9 per cent growth in its profit after tax to Rs 789 crore for the quarter ended September 2022, against Rs 711 crore in the year-ago period.
This is in addition to the donations being offered by Lilly to the Indian government that will potentially help alleviate the burden of COVID-19, Visini said.
With this deal, Cipla is aiming to reach out to wider customers located in small towns and other far-fetched locations.
Indian pharmaceutical manufacturers, Jubilant Life Sciences, Cipla Ltd, Hetero Labs Ltd and Mylan and Pakistani firm Ferozsons Laboratories have signed the commercial agreement that allows the companies to manufacture remdesivir for distribution in 127 countries, including India.
